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ABSTRACT
Antidrug antibodies have been shown to be associated with a loss of response during biologic therapy. Despite
the potential association, there has been no report on the simultaneous monitoring of the following parameters in
psoriasis: presence of neutralizing antibodies, plasma tumor necrosis factor (TNF)-a concentration, TNFi concen-
tration and disease activity. Plasma concentrations of adalimumab, infliximab, etanercept and their respective
antidrug antibodies, as well as plasma concentrations of TNF-a were measured in 77 psoriasis patients receiving
biologic therapy, and the values were correlated with the clinical activity of the skin disease. Antidrug antibodies
were identified in the plasma of 25% of infliximab-treated patients and 29.6% of adalimumab-treated patients, but
not in the etanercept group. Clinical severity scores were significantly higher in the antibody-positive patients. In
patients receiving infliximab or adalimumab therapy, the presence of antidrug antibodies was directly associated
with reduced plasma TNF-inhibitor concentration and elevated plasma TNF-a level.
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INTRODUCTION
Biologic therapies targeting tumor necrosis factor (TNF)-a are
widely used in the treatment of psoriasis. To date, three TNF
inhibitors (TNFi) are registered for the treatment of plaque pso-
riasis: infliximab, adalimumab and etanercept. Infliximab, a
mouse–human chimeric monoclonal IgG1 antibody, and adali-
mumab, a fully human monoclonal immunoglobulin (Ig)G1 anti-
body, are specific for TNF. Etanercept is a fusion protein of
human TNF receptor-2 and human IgG1 Fc.1
It has been shown that administration of TNFi may lead to
the formation of antidrug antibodies (ADA) and the develop-
ment of an immune response.2 The presence of ADA has been
associated with decreased plasma drug level and a partial or
complete loss of response in psoriasis patients.3,4 Antibodies
against etanercept have no apparent effects on clinical
response,5,6 whereas antibodies against infliximab or adali-
mumab have been associated with diminished clinical
response.4,7
Despite the apparent link between the presence of ADA, the
plasma TNFi concentration and the clinical activity of the skin
symptoms, there has been no report as yet on the simultane-
ous monitoring of these parameters together with the plasma
TNF-a concentration in psoriasis patients. Therefore, we per-
formed a cross-sectional study to determine the potential
correlation between the plasma levels of TNF-a, the extent of
antibody formation against adalimumab, infliximab and etaner-
cept, and the plasma trough concentration of the TNFi in
patients with plaque psoriasis.
METHODS
Subjects
This study was approved by the internal review board of the
University of Szeged. Informed consent was obtained from all
participants, and the study was conducted in full accordance
with the principles of the Declaration of Helsinki and biologic
therapeutic guidelines. Caucasian psoriasis patients treated for
at least 12 weeks with a TNFi (infliximab, adalimumab or etan-
ercept) at the Department of Dermatology and Allergology of
the University of Szeged were enrolled in the study between
October 2011 and January 2012. To be eligible for biologic
treatment in Hungary, patients must fulfill the Hungarian
national guidelines criteria: diagnosis of psoriasis vulgaris; sev-
ere psoriasis documented as Psoriasis Area and Severity Index
(PASI) of more than 15, Dermatology Life Quality Index of more
than 10 or affected body surface area of more than 10%; lack
of efficacy or intolerance to phototherapy or methotrexate,
cyclosporin or acitretin treatments. Demographic and clinical
data of the patients are presented in Table 1. PASI scores at
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the initiation of the patients’ first and current biologic therapy
were retrieved from the patients’ records. PASI scores were
also calculated at the time of study enrolment.
Measuring plasma TNF-a and TNFi trough
concentrations and detecting ADA
Blood samples (5–10 mL) were obtained from patients on the
days of scheduled infusion/injection. To ensure that the trough
or residual plasma drug concentration was measured, blood
was drawn a few hours before the scheduled administration of
the TNFi. Plasma aliquots separated from the blood samples
were frozen at 20°C. The plasma concentrations of TNF-a
and the biologic therapeutic agent (infliximab, adalimumab or
etanercept), and the presence of IgG-type ADA were deter-
mined by using an enzyme-linked immunosorbent assay
(ELISA), in accordance with the manufacturer’s recommenda-
tions (Matriks Biotek Laboratories, Ankara, Turkey). For the
detection of ADA (antibodies to infliximab/adalimumab/etaner-
cept), indirect ELISA methodology was used. In these assays,
infliximab/adalimumab/etanercept is coated on the wall of the
microtiter wells. During the first incubation period, antidrug
antibodies are captured by binding to the drugs. After washing
away the unbound components from samples, a peroxidase-
labeled ADA-specific conjugate is added to each well and then
incubated. The bound enzymatic activity is detected by addi-
tion of tetramethylbenzidine (TMB) chromogen substrate. For
detecting plasma infliximab/adalimumab/etanercept, solid
phase ELISA, based on the sandwich principle, were used.
Standards and samples are incubated in the microtiter plate
coated with a monoclonal antibody or reactant specific for
infliximab/adalimumab/etanercept. After incubation, the wells
are washed. A horse radish peroxidase conjugated (in case of
infliximab and adalimumab) or a biotin-labeled (in case of etan-
ercept) tracer monoclonal antibody against the TNFi drug is
added and binds to the TNFi captured by the first monoclonal
antibody or reactant on the surface of the wells. Following
incubation, wells are washed and then the bound enzymatic
activity is detected by addition of chromogen substrate. The
TNF-a determination kit was also based on double monoclonal
antibody sandwich assay. TNF-a is captured by a monoclonal
antibody to human TNF-a coated on the wall of the microtiter
wells, and detected by a second, peroxidase-labeled mono-
clonal antibody. The bound enzymatic activity is detected by
addition of TMB chromogen substrate. According to the manu-
facturer, these assays detect only free plasma TNF-a, etaner-
cept, infliximab, adalimumab or ADA levels, while TNFi–TNF-a
or ADA–TNFi complexes are not measured.
Statistical analysis
The plasma concentrations of TNF-a, the trough concentra-
tions of the TNFi and the presence of ADA were correlated
with the patients’ epidemiological and clinical data. Data were
evaluated with the MedCalc version 12.2.1.0 (MedCalc Soft-
ware, Ostend, Belgium) and SPSS version 15.0 (SPSS, Chi-
Table 1. Basic demographic and clinical data from the study population
Treatment groups Etanercept (n = 22) Infliximab (n = 28) Adalimumab (n = 27) Total (n = 77)
Age (years)† 46.6  12.6 (21–73) 51.2  12.7 (26–78) 48  15.7 (23–76) 48.8  13.7 (21–78)
Male patients (%) 13 (59.1) 17 (60.7) 17 (63) 46 (61.0)
Bodyweight (kg)† 85.7  24.1 (54–156) 93.7  20.5 (52–143) 88.7  18.8 (54–130) 89.7  21.0 (52–156)
BMI† 27.7  5 (20.2–38.5) 32.4  7.3 (18.4–53.9) 30.1  5.3 (20.8–42.2) 30.2  6.3 (18.4–53.9)
Patients with a history
of smoking (%)
8 (36.4) 10 (35.7) 10 (37) 28 (36.4)
Duration of current biologic
therapy (months)†
28.4  18.8 (5–66) 19.9  16.4 (3–63) 17.8  10.4 (3–39) 21.6  15.8 (3–66)
Patients receiving a
different biologic
therapy previously (%)
8 (36.4) 8 (28.6) 20 (74.1) 36 (46.7)
Previous biologic therapies Infliximab: 3 Etanercept: 2 Etanercept: 4
Adalimumab: 2 Adalimumab: 4 Infliximab: 10
Efalizumab: 1 Efalizumab: 1 Etanercept, infliximab: 3
Ustekinumab: 2 Adalimumab, etanercept: 1 Etanercept, efalizumab: 2
Efalizumab: 1
PASI score at induction of
first biologic therapy†
16.6  4.6 (9.6–25.6) 18.4  5.6 (9.3–32.7) 20.8  9.2 (4.1–52.1) 18.7  7.0 (4.1–52.1)
PASI score at induction of
current biologic therapy†
14.7  5.7 (1.2–25.6) 17.9  5.5 (9.3–32.7) 15.0  5.0 (5.8–26) 16.0  5.5 (1.2–32.7)
Patients with psoriatic
arthritis (%)
7 (31.8) 13 (46.4) 14 (51.9) 34 (44.2)
Patients receiving
concomitant
immunosuppressive
therapy (%)
0 (0) 8 (28.6) 1 (3.7) 9 (11.7)
†Mean  standard deviation. BMI, body mass index; PASI, Psoriasis Area and Severity Index.
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cago, IL, USA) statistical programs. ADA-positive and -negative
groups were analyzed using mixed factorial ANOVA and logistic
regression. For other differences between groups, the paired t-
test, the v2-test and Fisher’s exact test were performed, where
appropriate. P < 0.05 was considered statistically significant.
RESULTS
Patient characteristics
Of the 77 patients, 22 (28.6%), 28 (36.4%) and 27 (35.1%)
received etanercept, infliximab and adalimumab treatment,
respectively (Table 1). The maintenance dose was 5 mg/kg i.v.
every 8 weeks for infliximab, 40 mg s.c. every 2 weeks for
adalimumab and 50 mg s.c. every week for etanercept. The
groups receiving the three different TNFi treatments did not dif-
fer significantly in the following demographic and clinical char-
acteristics: mean age, sex ratio, mean bodyweight, mean body
mass index, proportion of smokers, mean duration of current
biologic therapy, mean PASI score at induction of first biologic
therapy, mean PASI score at induction of current biologic ther-
apy and presence of psoriatic arthritis. Before the current bio-
logic therapy, 30 patients received one, and six patients
received two biologic agents. The patients in the adalimumab
group had previously been treated significantly more frequently
with biologic therapy than those in the other treatment groups
(adalimumab vs etanercept, P < 0.05; adalimumab vs inflix-
imab, P < 0.01), while no statistically significant difference was
observed between the etanercept and infliximab groups
(P = 0.76) in this regard. Of the 77 patients, nine received con-
comitant disease-modifying antirheumatic drug (DMARD) ther-
apy (eight methotrexate and one leflunomide). Concomitant
DMARD therapy was more frequent in the infliximab group
than in the other two treatment groups.
ADA, plasma trough TNFi concentrations, plasma
TNF-a levels and clinical response
Antidrug antibodies were detected in 15 of the 77 patients
(19.5%): seven and eight in patients receiving infliximab and
adalimumab, respectively (Table 2). ADA were not identified in
any of the 22 patients receiving etanercept therapy. Interest-
ingly, most of the ADA (11/15) were detected in patients who
received the TNFi therapy for up to 12 months, although the
number of patients in this group was comparable with the
number of patients receiving treatment for more than
12 months (22 and 33, respectively; P < 0.01).
The mean plasma trough concentrations (i.e. residual con-
centrations prior to the next scheduled treatment) of adali-
mumab, etanercept and infliximab were 2.4  2.3 (range, 0–
6.9), 7.6  2.0 (range, 4.1–11.3) and 2.9  0.8 lg/mL (range,
2.2–5.0), respectively. The mean plasma trough concentration
of infliximab in ADA-negative patients was significantly higher
than in the ADA-positive patients (3.0  0.8 [range, 2.2–5.0]
and 2.3  0.1 lg/mL [range, 2.2–2.5], respectively [P < 0.05])
(Fig. 1a). In ADA-negative patients, the residual plasma adali-
mumab concentration was 2.8  2.3 lg/mL (range, 0–6.9),
whereas in ADA-positive patients it was 1.5  2.2 lg/mL
(range, 0–5.3) (P = 0.18) (Fig. 1b). As discussed in the previous
section, ADA were not detected in the etanercept group.
The mean plasma TNF-a concentration was significantly
lower in patients with negative anti-infliximab antibody status,
compared with ADA-positive patients (2.5  3.9 [range, 0–14.4]
and 13.2  12.9 pg/mL [range, 0–34.8], respectively; P < 0.05).
Similarly, anti-adalimumab antibody-negative patients demon-
strated a lower mean TNF-a concentration than the ADA-posi-
tive group (1.0  2.0 and 3.6  6.3 pg/mL, respectively;
P = 0.16). Interestingly, although patients receiving etanercept
were ADA-negative, their mean TNF-a level (7.0  6.3 pg/mL)
was significantly higher than that of ADA-negative patients
receiving either infliximab or adalimumab (infliximab, P < 0.01;
adalimumab, P < 0.001) (Fig. 2).
There was no statistically significant difference in the
mean PASI score at the initiation of the therapy between the
ADA-positive and -negative patients (data not shown). At the
time of sample collection, however, the mean PASI score of
the ADA-negative and the ADA-positive infliximab groups
was significantly different (1.6  1.6 vs 9.3  11.2, P < 0.05,
after adjusting for age and sex). Similarly, at the time of
sample collection, the average PASI score of the ADA-nega-
tive, adalimumab-treated patients was significantly lower
(2.4  3.5 vs 12.5  8.6, P < 0.01, after adjusting for age
and sex) (Fig. 3).
Patients who received their first biologic therapy during the
study (bio-naive patients), and patients who previously had
received biologic therapy (non-bio-naive patients) did not differ
Table 2. Duration of the actual treatment, mean TNF-a plasma level, mean plasma TNFi level and PASI scores of patients at the
time of sampling
Etanercept
(n = 22)
Adalimumab 
(n = 19)
Adalimumab +
(n = 8)
Infliximab 
(n = 21)
Infliximab +
(n = 7)
No. of patients with ≤12 months of TNFi treatment 4 5 5 6 6
No. of patients with >12 months of TNFi treatment 18 14 3 15 1
TNF-a plasma level (pg/mL)† 7.0  6.3 1.0  2.0 3.6  6.3 2.5  3.9 13.2  12.9
Plasma trough level of the TNFi (lg/mL)† 7.6  2.0 2.8  2.3 1.5  2.2 3.0  0.8 2.3  0.1
PASI score at sampling† 2.5  2.5 2.4  3.5 12.5  8.6 1.6  1.6 9.3  11.2
Change of PASI score from baseline (%)† 83.8  13.4 83.9  19.1 34.0  35.0 90.2  11.1 53.1  32.6
†Mean  standard deviation. –/+, patients without/with antidrug antibodies (ADA). PASI, Psoriasis Area and Severity Index; TNFi, tumor necrosis factor
inhibitor.
1020 © 2016 Japanese Dermatological Association
R. Kui et al.
significantly in their clinical responses, extent of ADA-positivity
and plasma TNF-a levels (data not shown).
DISCUSSION
The purpose of our cross-sectional study was to assess the
presence of ADA against TNFi, the plasma trough concentra-
tions of anti-TNF medications and the plasma TNF-a level dur-
ing the biologic therapy of psoriasis, and their impact on the
clinical efficacy.
Our results, that anti-infliximab or anti-adalimumab antibod-
ies were detected in 25.0% and 28.6% of the respective
patients, while ADA were not found against etanercept, are in
agreement with previous reports.3–12 The clinical improvement
among ADA-positive patients was significantly lower than in
the ADA-negative groups. Previous studies similarly demon-
strated significantly lower clinical efficacy of infliximab and
(a)
(b)
Figure 1. Mean plasma trough concentrations of the tumor
necrosis factor inhibitor (TNFi) in the antidrug antibodies (ADA)-
negative and -positive patients receiving (a) infliximab or (b)
adalimumab therapy. The mean residual infliximab plasma con-
centration was significantly lower (2.3  0.1 lg/mL) in the
patients with anti-infliximab antibodies than in the ADA-nega-
tive patients (3.0  0.8 lg/mL). In the case of adalimumab, the
plasma trough adalimumab concentration was higher in the
ADA-negative patients (2.8  2.3 vs 1.5  2.2 lg/mL), but the
difference was not statistically significant. *P < 0.05.
Figure 2. Plasma tumor necrosis factor (TNF)-a levels at the
time of blood sampling in the etanercept and antidrug antibod-
ies (ADA)-negative and -positive groups receiving adalimumab
or infliximab. In the anti-infliximab antibody-negative patients
() the mean TNF-a concentration was 2.5  3.9 pg/mL
(range, 0–14.4), while that in the anti-infliximab antibody-posi-
tive group (+) was 13.2  12.9 pg/mL (range, 0–34.8). In the
adalimumab-treated group, the mean TNF-a concentration was
lower in the antibody-negative patients () than in the anti-ada-
limumab antibody-positive group (+) (1.0  2.0 and
3.6  6.3 pg/mL, respectively). *P < 0.05.
Figure 3. Psoriasis Area and Severity Index (PASI) scores at
the time of blood sampling in the etanercept and antidrug anti-
bodies (ADA)-negative and -positive adalimumab and infliximab
groups. The mean PASI score at the time of blood sampling
was significantly lower in the ADA-negative patients in both the
infliximab and adalimumab groups (infliximab, 1.6  1.6 vs
9.3  11.2; adalimumab, 2.4  3.5 vs 12.5  8.6 in the ADA-
negative vs -positive patients, respectively). *P < 0.05,
**P < 0.01.
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adalimumab among ADA-positive patients,4,7,8,12–14 as well as
a clear correlation between decreased plasma infliximab level
and poorer therapeutic outcome.13 Our observation that the
plasma trough TNFi concentrations are lower in ADA-positive
patients treated with infliximab and adalimumab fully supports
these previous findings. The structure of the biologic agent is
one of the most important factors determining the immuno-
genicity and the binding of ADA. Even though we have not
detected neutralizing antibodies against etanercept, non-neu-
tralizing ADA have been shown to form in etanercept
patients.15 As these antibodies bind to the fusion region of
etanercept, they leave the TNF-binding site free, and, thus, the
function of etanercept remains uncompromised. However, as
these immune complexes can cause quicker drug elimination,
their formation may result in lower plasma trough levels and
diminished therapeutic efficacy.2,16
Although the clinical activity of psoriasis was almost equal in
the three treatment groups, the mean plasma TNF-a levels dif-
fered considerably. The lowest mean concentrations were
measured in the adalimumab group and the highest in the
etanercept treatment group. Interestingly, Kim et al.17 also
describe this paradoxical phenomenon in a recent paper: they
report that serum TNF-a concentrations in psoriasis patients
increased after 12 weeks of etanercept treatment. In their opin-
ion, serum TNF-a level after etanercept treatment reflected the
summation of circulating TNF-a–etanercept complexes with
pretreatment free TNF-a levels. This could be a plausible
explanation to our finding as well, however, the ELISA kits
used in our experiments (according to the manufacturer) only
detect free TNF-a (TNFi–TNF-a complexes are not measured).
Obviously, either the ELISA kits after all detect both free and
bound plasma TNF-a, or there are other, currently unknown
mechanisms which lead to increased TNF levels during etaner-
cept treatment. As we did not find any direct correlation
between clinical activity (PASI score) and the measured plasma
TNF-a levels in our cohort of etanercept-treated patients, this
latter explanation, however, seems more unlikely. The mean
plasma TNF-a concentration was significantly higher among
the ADA-positive infliximab- and adalimumab-treated patients
than among the ADA-negative patients. Notably, this study has
not established a clear statistical correlation between the
plasma TNF-a level and the clinical activity of psoriasis during
TNFi therapy. This result may be due in part to our relatively
small study population, as patients who responded well tended
to have lower TNF-a levels. It must also be considered, how-
ever, that the plasma TNF-a concentration is not necessarily
associated directly with the efficacy of TNFi therapy. Other
indicators (such as the TNF-a concentration in the lesional pso-
riatic skin) may correlate more closely with the clinical activity
of psoriasis during anti-TNF treatment. A recent report clearly
showed that TNF blockers decrease the activity of multiple
pro-inflammatory pathways in lesional skin, including the acti-
vation and maturation of dendritic cells, the activation of T lym-
phocytes, and the production of different cytokines, growth
factors and chemokines.18
The design of the present study obviously differed from
those in previously reported investigations, and this must be
taken into consideration while analyzing the data. Samples
were not collected at standardized treatment points (e.g. at
week 0, 12 or 52) as in most previously reported studies, but
during the patients’ scheduled visits. While sample collection
at standardized time points makes the data more homoge-
neous, it also involves certain methodical problems. As it
would be unethical to continue the treatment of patients with a
significant loss of response, these patients are often excluded
from the analysis, and important data are therefore lost. More-
over, owing to their prospective nature, most of these investi-
gations collect samples for only up to 52 weeks of treatment.
The cross-sectional nature of the sample collection that we
used, in contrast, allowed data collection even when the
patients subsequently stopped the treatment due to the loss of
efficacy. The sample homogeneity, of course, was not as high
as in previous reports; however, as the patients appeared in
random order for the appointments, the heterogeneity was bal-
anced among the different analysis groups. Another advantage
of our sample collection strategy was that the presence of
ADA could be analyzed over a relatively long period of TNFi
therapy (12–264 weeks). This allowed us to determine that anti-
body positivity is significantly more frequent among patients
treated for less than 12 months. This observation suggests that
the risk of ADA development is much higher during the first
year of therapy. Consequently, the loss of therapeutic response
after the first 12 months of TNFi therapy is likely to be caused
by factors other than ADA. In these cases of late loss of effi-
cacy, therefore, other possible factors (e.g. infection, non-
adherence to treatment) should additionally be considered.
The main limitation of our cross-sectional approach is that
patients recruited into this study might have represented a bias
towards satisfactory clinical response to treatment. Patients
with high antibody titers and consequent loss of response are
likely to have a lower drug survival and are more likely to dis-
continue use of the drug. In contrast, patients using the bio-
logic drug successfully for long periods of time are more likely
to have undetectable levels of antibodies. By enrolling patients
receiving treatment for at least 3 months, a positive selection
bias might have been implemented.
Because of its ease of use, ELISA is the preferred method
to measure the level of ADA. However, standard direct and
indirect ELISA carry the disadvantage of producing non-speci-
fic binding and false-positive results.19 According to the pub-
lished work, two assays stand out in terms of sensitivity and
specificity: the bridging ELISA and the radioimmunoassay
(RIA). RIA (and particularly its special format, the two-site
assay) has very high specificity, and in addition, this method is
less sensitive for drug interference than the bridging ELISA.
Yet, a disadvantage is that the use of radioactivity hampers its
broad application. Bridging ELISA reduce background readings
by the requirement for two specific binding events for the tar-
get drug, which increases specificity of the assay.20
In conclusion, this study has provided evidence that the
development of ADA during infliximab or adalimumab treat-
ment of psoriasis is directly associated with reduced plasma
TNFi concentration and increased plasma TNF-a level. A higher
plasma TNF-a concentration may consequently lead to a wors-
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ening of the clinical symptoms of psoriasis. Clarification of
whether the TNF-a concentration in the peripheral blood of
patients receiving TNFi therapy is a direct indicator of the clini-
cal activity of psoriasis demands further investigation. Further-
more, an increasing body of evidence supports the conclusion
that monitoring the plasma drug level and the presence of ADA
in daily clinical practice can aid therapeutic decisions during
the TNFi treatment of plaque psoriasis.
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